# Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

> **NCT07656376** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Jiangxi Kvvit Pharmaceutical Co., Ltd.** · enrollment: 465 (estimated)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Carcinoma

## Interventions

- **DRUG:** DN022150+AG( Stage I ）
- **DRUG:** DN022150+AG（Stage II）
- **DRUG:** placebo+AG（Stage II）

## Key facts

- **NCT ID:** NCT07656376
- **Lead sponsor:** Jiangxi Kvvit Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-06-06
- **Primary completion:** 2029-02-07
- **Final completion:** 2029-05-08
- **Target enrollment:** 465 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07656376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07656376, "Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07656376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*